Objective: The presence of BRCA gene mutation and low expressions of BRCA proteins are associated with a greater sensitivity of tumor cells to ionizing radiation and to cytostatics damaging the DNA of the cells. The purpose of this study was to estimate the rate of adverse events in BRCA1/2-associated breast cancer patients receiving anthracycline-based chemotherapy compared to patients without mutation. The authors also compared radiotherapy toxicity in these 2 groups. Methods: The analysis included 270 early-stage breast cancer patients treated between 2006 and 2012. All patients were examined for the presence of BRCA1/2 mutations. Results:BRCA mutation was detected in 41 (15%) patients. Toxicity grade 3, especially nausea and vomiting, was observed more often in noncarriers (7 vs. 13%, p = 0.0008). Neutropenia was detected more frequently in patients with BRCA1/2 mutation (32 vs. 10%), but only after 1 cycle of chemotherapy (p = 0.0007). There was increased radiation toxicity in BRCA1/2 patients who underwent mastectomy and neoadjuvant chemotherapy (p = 0.016). Conclusions:BRCA1/2 mutation carriers seemed to be more at risk of neutropenia after the first cycle of the treatment. In terms of other side effects, there was a lack of increased toxicity in this group. Mastectomy and neoadjuvant chemotherapy were risk factors for radiation toxicity in mutation carriers.

Keywords:
Breast cancer, BRCA1/2, Toxicity, Anthracyclines, Radiotherapy
1.
Foulkes WD: BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Familial Cancer 2006;5:135-142.
2.
Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD: A significant response to neoadjuvant chemotherapy in BRCA1/2-related breast cancer. J Med Genet 2002;39:608-610.
3.
Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, Lubinski J, Narod SA: Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012;14:R110.
4.
Powell SN, Kachnic LA: Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003;22:5784-5791.
5.
Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. JNCI J Natl Cancer Inst 2004;96:1659-1668.
6.
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
7.
Wang TH, Wang HS, Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000;88:2619-2628.
8.
Kurebayashi J, Yamamoto Y, Kurosumi M, Okubo S, Nomura T, Tanaka K, Sonoo H: Loss of BRCA expression may predict shorter time to progression in metastatic breast cancer patients treated with taxanes. Anticancer Res 2006;26:695-701.
9.
Robson ME: Should the presence of germline BRCA1/2 mutations influence treatment selection in breast cancer? J Clin Oncol 2011;29:3724-3726.
10.
Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Gui G; Breast Unit of the Royal Marsden NHS Foundation Trust, Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R: Late toxicity is not increased in BRCA1/BRCA2 mutation carries undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 2006;12:7025-7032.
11.
Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D, Solin LJ, Nixon A, Garber J, Berg C, Isaacs C, Heimann R, Olopade OI, Haffty B, Weber BL: Effect of radiotherapy after breast conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000;18:3360-3369.
12.
Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska Ł, Haus O, Janiszewska H, Niepsuj S, Góźdź S, Zaremba L, Posmyk M, Płuzańska M, Kilar E, Czudowska D, Waśko B, Miturski R, Kowalczyk JR, Urbański K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C: A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004;110:683-686.
13.
Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siołek M, Dent R, Lubiński J, Narod S: Pathologic complete response rates in young women with BRCA1-positive breast cancer after neoadjuvant chemotherapy. J Clin Oncol 2012;28:375-379.
14.
Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, Asselain B, Stoppa-Lyonnet D, Fourquet A: Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat 2010;120:119-126.
15.
Bertwistle D, Ashworth A: Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev 1998;8:14-20.
16.
Gaffney DK, Brohet RM, Lewis CM, Holden JA, Buys SS, Neuhausen SL, Steele L, Avizonis V, Stewart JR, Cannon-Albright LA: Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA1 mutations. Radiother Oncol 1998;47:129-136.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.